Cancer screening typically requires large, expensive equipment housed in specialized facilities. Current methods rely on chemical analysis of blood samples, microscopic examination of tissue biopsies, or complex imaging machines. Each approach demands extensive infrastructure: clinical laboratories, expensive equipment, and highly trained specialists to prepare samples and interpret results. These requirements create significant barriers to regular screening, particularly in regions with limited medical resources.
